Your browser doesn't support javascript.
loading
ADGRL1 haploinsufficiency causes a variable spectrum of neurodevelopmental disorders in humans and alters synaptic activity and behavior in a mouse model.
Vitobello, Antonio; Mazel, Benoit; Lelianova, Vera G; Zangrandi, Alice; Petitto, Evelina; Suckling, Jason; Salpietro, Vincenzo; Meyer, Robert; Elbracht, Miriam; Kurth, Ingo; Eggermann, Thomas; Benlaouer, Ouafa; Lall, Gurprit; Tonevitsky, Alexander G; Scott, Daryl A; Chan, Katie M; Rosenfeld, Jill A; Nambot, Sophie; Safraou, Hana; Bruel, Ange-Line; Denommé-Pichon, Anne-Sophie; Tran Mau-Them, Frédéric; Philippe, Christophe; Duffourd, Yannis; Guo, Hui; Petersen, Andrea K; Granger, Leslie; Crunk, Amy; Bayat, Allan; Striano, Pasquale; Zara, Federico; Scala, Marcello; Thomas, Quentin; Delahaye, Andrée; de Sainte Agathe, Jean-Madeleine; Buratti, Julien; Kozlov, Serguei V; Faivre, Laurence; Thauvin-Robinet, Christel; Ushkaryov, Yuri.
Afiliação
  • Vitobello A; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Mazel B; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Lelianova VG; Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham ME4 4TB, UK; Department of Life Sciences, Imperial College London, London, UK.
  • Zangrandi A; Department of Life Sciences, Imperial College London, London, UK.
  • Petitto E; Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham ME4 4TB, UK.
  • Suckling J; Department of Life Sciences, Imperial College London, London, UK.
  • Salpietro V; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
  • Meyer R; Institute of Human Genetics, Medical Faculty, RWTH Aachen, Aachen, Germany.
  • Elbracht M; Institute of Human Genetics, Medical Faculty, RWTH Aachen, Aachen, Germany.
  • Kurth I; Institute of Human Genetics, Medical Faculty, RWTH Aachen, Aachen, Germany.
  • Eggermann T; Institute of Human Genetics, Medical Faculty, RWTH Aachen, Aachen, Germany.
  • Benlaouer O; Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham ME4 4TB, UK.
  • Lall G; Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham ME4 4TB, UK.
  • Tonevitsky AG; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia.
  • Scott DA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Chan KM; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Rosenfeld JA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Nambot S; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; Centre de Génétique et Centre de Référence Anomalies du Développement
  • Safraou H; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Bruel AL; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Denommé-Pichon AS; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Tran Mau-Them F; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Philippe C; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Duffourd Y; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Guo H; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China; Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
  • Petersen AK; Randall Children's Hospital, Portland, OR, USA.
  • Granger L; Randall Children's Hospital, Portland, OR, USA.
  • Crunk A; GeneDx, Inc., Gaithersburg, MD, USA.
  • Bayat A; Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Dianalund, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Striano P; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy; Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Zara F; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy; Medical Genetics Unit, IRCSS Istituto Giannina Gastini, Genoa, Italy.
  • Scala M; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy; Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Thomas Q; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; Centre de Génétique et Centre de Référence Déficiences Intellectuelle
  • Delahaye A; UF médecine génomique et génétique clinique, Hôpital Jean Verdier, Hôpitaux Universitaires de Paris Seine Saint Denis, AP-HP, Bondy, France; UFR de Santé Médecine et Biologie humaine, Université Sorbonne Paris Nord, Bodigny, France; NeuroDiderot UMR 1141, Inserm, FHU I2-D2, Université de Paris, Pari
  • de Sainte Agathe JM; Département de Génétique Médicale, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
  • Buratti J; Département de Génétique Médicale, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
  • Kozlov SV; Center for Advanced Preclinical Research, National Cancer Institute, Frederick, MD, USA.
  • Faivre L; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; Centre de Génétique et Centre de Référence Anomalies du Développement
  • Thauvin-Robinet C; Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne - Université de Bourgogne, Dijon, France; UF Innovation en diagnostic génomique des maladies rares, CHU Dijon B
  • Ushkaryov Y; Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham ME4 4TB, UK; Department of Life Sciences, Imperial College London, London, UK; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia. Electronic address: y.ushkaryov@kent.ac.uk.
Am J Hum Genet ; 109(8): 1436-1457, 2022 08 04.
Article em En | MEDLINE | ID: mdl-35907405
ABSTRACT
ADGRL1 (latrophilin 1), a well-characterized adhesion G protein-coupled receptor, has been implicated in synaptic development, maturation, and activity. However, the role of ADGRL1 in human disease has been elusive. Here, we describe ten individuals with variable neurodevelopmental features including developmental delay, intellectual disability, attention deficit hyperactivity and autism spectrum disorders, and epilepsy, all heterozygous for variants in ADGRL1. In vitro, human ADGRL1 variants expressed in neuroblastoma cells showed faulty ligand-induced regulation of intracellular Ca2+ influx, consistent with haploinsufficiency. In vivo, Adgrl1 was knocked out in mice and studied on two genetic backgrounds. On a non-permissive background, mice carrying a heterozygous Adgrl1 null allele exhibited neurological and developmental abnormalities, while homozygous mice were non-viable. On a permissive background, knockout animals were also born at sub-Mendelian ratios, but many Adgrl1 null mice survived gestation and reached adulthood. Adgrl1-/- mice demonstrated stereotypic behaviors, sexual dysfunction, bimodal extremes of locomotion, augmented startle reflex, and attenuated pre-pulse inhibition, which responded to risperidone. Ex vivo synaptic preparations displayed increased spontaneous exocytosis of dopamine, acetylcholine, and glutamate, but Adgrl1-/- neurons formed synapses in vitro poorly. Overall, our findings demonstrate that ADGRL1 haploinsufficiency leads to consistent developmental, neurological, and behavioral abnormalities in mice and humans.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Peptídeos / Receptores Acoplados a Proteínas G / Transtornos do Neurodesenvolvimento / Transtorno do Espectro Autista / Deficiência Intelectual Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adult / Animals / Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Peptídeos / Receptores Acoplados a Proteínas G / Transtornos do Neurodesenvolvimento / Transtorno do Espectro Autista / Deficiência Intelectual Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adult / Animals / Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2022 Tipo de documento: Article